@article{a8144d6240d2488e9e9825ff184f6937,
title = "Whole exome sequencing analysis in severe chronic obstructive pulmonary disease",
abstract = "Chronic obstructive pulmonary disease (COPD), one of the leading causes of death worldwide, is substantially influenced by genetic factors. Alpha-1 antitrypsin deficiency demonstrates that rare coding variants of large effect can influence COPD susceptibility. To identify additional rare coding variants in patients with severe COPD, we conducted whole exome sequencing analysis in 2543 subjects from two family-based studies (Boston Early-Onset COPD Study and International COPD Genetics Network) and one case–control study (COPDGene). Applying a gene-based segregation test in the family-based data, we identified significant segregation of rare loss of function variants in TBC1D10A and RFPL1 (P-value < 2x10–6), but were unable to find similar variants in the case–control study. In single-variant, gene-based and pathway association analyses, we were unable to find significant findings that replicated or were significant in meta-analysis. However, we found that the top results in the two datasets were in proximity to each other in the protein–protein interaction network (P-value = 0.014), suggesting enrichment of these results for similar biological processes. A network of these association results and their neighbors was significantly enriched in the transforming growth factor beta-receptor binding and cilia-related pathways. Finally, in a more detailed examination of candidate genes, we identified individuals with putative high-risk variants, including patients harboring homozygous mutations in genes associated with cutis laxa and Niemann–Pick Disease Type C. Our results likely reflect heterogeneity of genetic risk for COPD along with limitations of statistical power and functional annotation, and highlight the potential of network analysis to gain insight into genetic association studies.",
author = "Dandi Qiao and Asher Ameli and Dmitry Prokopenko and Han Chen and Kho, {Alvin T.} and Parker, {Margaret M.} and Jarrett Morrow and Hobbs, {Brian D.} and Yanhong Liu and Beaty, {Terri H.} and Crapo, {James D.} and Barnes, {Kathleen C.} and Nickerson, {Deborah A.} and Michael Bamshad and Hersh, {Craig P.} and Lomas, {David A.} and Alvar Agusti and Make, {Barry J.} and Calverley, {Peter M.A.} and Donner, {Claudio F.} and Wouters, {Emiel F.} and J{\o}rgen Vestbo and Par{\'e}, {Peter D.} and Levy, {Robert D.} and Rennard, {Stephen I.} and Ruth Tal-Singer and Spitz, {Margaret R.} and Amitabh Sharma and Ingo Ruczinski and Christoph Lange and Silverman, {Edwin K.} and Cho, {Michael H.}",
note = "Funding Information: NHLBI (R01 HL089856 to E.K.S., R01 HL089897 to J.D.C., R01 HL113264 to M.H.C. and E.K.S., P01 HL105339 to E.K.S., PO1 114501 to E.K.S, K01 HL129039 to D.Q., K07 CA181480 to Y.L.); GlaxoSmithKline; National Human Genome Research Institute and the National Heart, Lung and Blood Institute (grant 1U54HG006493). Funding Information: The COPDGene project (NCT00608764) is supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion. Authors would like acknowledge Victor M Pinto-Plata (Baystate Medical Center, Springfield, MA), Nathaniel Marchetti (Temple University School of Medicine, Philadelphia, PA), Raphael Bueno(Brigham and Women{\textquoteright}s Hospital and Harvard Medical School, Boston, MA), Bartolome R. Celli (Brigham and Women{\textquoteright}s Hospital and Harvard Medical School, Boston, MA), Gerald J. Criner (Temple University School of Medicine, Philadelphia, PA) and Dawn Demeo (Brigham and Women{\textquoteright}s Hospital and Harvard Medical School, Boston, MA) for providing the lung tissue samples and their support of the project. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. NHLBI (R01 HL089856 to E.K.S., R01 HL089897 to J.D.C., R01 HL113264 to M.H.C. and E.K.S., P01 HL105339 to E.K.S., PO1 114501 to E.K.S, K01 HL129039 to D.Q., K07 CA181480 to Y.L.); GlaxoSmithKline; National Human Genome Research Institute and the National Heart, Lung and Blood Institute (grant 1U54HG006493). Funding Information: The COPDGene project (NCT00608764) is supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens and Sunovion. Authors would like acknowledge Victor M Pinto-Plata (Baystate Medical Center, Springfield, MA), Nathaniel Marchetti (Temple University School of Medicine, Philadelphia, PA), Raphael Bueno(Brigham and Women{\textquoteright}s Hospital and Harvard Funding Information: Conflict of Interest statement. Dr. Silverman has received honoraria and consulting fees from Merck, grant support and consulting fees from GlaxoSmithKline, and honoraria from Novartis. Dr. Hersh has been a consultant for CSL Behring and Mylan. Dr. Cho has received grant support from GSK. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press. All rights reserved.",
year = "2018",
month = nov,
day = "1",
doi = "10.1093/hmg/ddy269",
language = "English (US)",
volume = "27",
pages = "3801--3812",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "21",
}